AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.
Tag Archive for: AbbVie
While reporting positive third-quarter financials, AbbVie announced it is halting the development of cedirogant (ABBV-157), while also providing updates on Skyrizi, Rinvoq and Humira.
Seattle-based Alpine Immune Sciences voluntarily terminated enrollment in two clinical trials of its immuno-oncology asset, davoceticept, after a second patient death. The company now plans to focus its attention on ALPN-303 for autoantibody-related inflammatory diseases.
The top pharma companies in 2021 continued to be engaged in creating vaccines and therapeutics, and the investments in R&D led to greater revenue and earnings.
AbbVie may have doubled in size since the Allergan acquisition, but nearly half the company’s revenue, and a large chunk of its potential future growth, are still coming from a familiar place.
As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.
Six months after its official launch by Flagship Ventures, Massachusetts-based Vesalius Therapeutics is laying off 43% of its staff. With a current headcount of 67, the company is slashing 29 jobs.
Both Bristol-Myers Squibb and AbbVie separately filed notices with the California state government stating they intend to lay off up to 360 people in the state.
The U.S. Food and Drug Administrationon Thursday approved Revance Therapeutics’ anti-wrinkle injection, setting up a challenger for market leader AbbVie’s Botox that has long dominated the aesthetic market.
I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.